-
Novavax Update Fails To Impress; This Is Now A 'Show Me Story'
Tuesday, July 25, 2017 - 12:02pm | 301Read More...Two analysts reiterated their Neutral ratings on Novavax, Inc. (NASDAQ: NVAX) after the company announced what it said was positive data for its phase 2 safety and immunogenicity trial of its RSV F vaccine. Novavax was down 24.5 percent and trading at $1.14 at the time of writing, one day after...
-
Thoughts On Synergy Pharma's Valuation As Cantor Initiates At Overweight
Friday, June 2, 2017 - 9:49am | 294Read More...Cantor Fitzgerald initiated coverage of Synergy Pharmaceuticals Inc (NASDAQ: SGYP) at Overweight with a price target of $11. Analyst William Tanner estimates second quarter earnings of $1.4 million with a negative $0.25 EPS. Fiscal 2017 earnings are estimated to be $11.3 million. Opportunities In...
-
Analyst: The Nature Of TherapeuticsMD 's CRL From The FDA Is A 'Best-Case Scenario'
Tuesday, May 9, 2017 - 9:20am | 408Read More...On Monday, TherapeuticsMD Inc (NYSE: TXMD) received a Complete Response Letter from the FDA related to the company’s New Drug Application for TX-004HR. TX-004HR is a applicator-free estradiol vaginal softgel capsule used to treat moderate-to-severe sexual intercourse pain caused by vulvar and...
-
For A Tarnished Novavax, An Effective Zika Vaccine Could Be The Only Cure
Thursday, January 12, 2017 - 2:21pm | 351Read More...Cantor Fitzgerald believes only an effective Zika vaccine could revive Novavax, Inc. (NASDAQ: NVAX), which reported failure of its respiratory disease vaccine in a late stage study in September. The company’s RSV F-protein recombinant nanoparticle vaccine candidate, which failed to hit both...
-
TherapeuticsMD Shares Rally +27% On FBR's Initiation
Tuesday, July 8, 2014 - 2:49pm | 129Read More...Shares of TherapeuticsMD (NYSE: TXMD) gained 27.6 percent following FBR's initiation. FBR analyst William Tanner initiated coverage on TherapeuticsMD with an Outperform rating and $34.00 price target. Tanner reported that TherapeuticsMD's TX-001 is likely the only FDA approved bio-...
-
FBR Capital Markets Comments on Shire PLC Following Announcement of ViroPharma Acquisition
Tuesday, November 12, 2013 - 10:05am | 131Read More...In a report published Tuesday, FBR Capital Markets analyst William Tanner commented on recent developments related to Shire PLC (NASDAQ: SHPG). In the report, FBR Capital Markets noted, “The announcement that Shire plans to acquire ViroPharma probably comes as little surprise to many investors,...
